List view / Grid view
Preclinical drug target validation has the aim to increase confidence in a particular drug target. The process proves the initial hypothesis that a particular molecular target is key or even causative for pathogenic or symptomatic mechanisms in a disease. Several success factors seem to be of particular importance for the…
Chemokines orchestrate leukocyte trafficking in the immune system, but unregulated or inappropriate chemokine activity plays a key role in many inflammatory, allergic and autoimmune diseases as well as metastatic tumour progression. The chemokine network is comprised of ~50 distinct ligands that specifically bind and activate a family of 20 G…
3 April 2014 | By Daiichi Sankyo
Daiichi Sankyo Co., Ltd. and University of California, San Francisco announced that they have established a drug discovery collaboration focused on developing novel therapeutics and molecular diagnostics for multiple neurodegenerative diseases...
31 March 2014 | By AstraZeneca
AstraZeneca and the Medical Research Council announced that they have entered into a groundbreaking collaboration aimed at better understanding the mechanisms of human disease...
28 March 2014 | By Freddy White, Drug Target Review
Freddy White, Director, European Pharmaceutical Review & Drug Target Review speaks with Rohit Shroff, Application Specialist, Tecan at Pittcon 2014...
28 March 2014 | By Freddy White, Drug Target Review
Freddy White, Director, European Pharmaceutical Review & Drug Target Review Speaks With Richard Ladd, Senior Director pharmaceutical operations, Waters at Pittcon 2014...
19 March 2014 | By Daiichi Sankyo
Astellas Pharma Inc. and Daiichi Sankyo Company, Limited announced the companies would form a compound library sharing partnership for approximately 400,000 selected compounds...
27 February 2014 | By Freddy White, Drug Target Review
Michael Bjerke, Promega's Global Product Manager, Detection, speaks to Freddy White at SLAS 2014.
27 February 2014 | By Freddy White, Drug Target Review
Chris Parker, CCO at Cellular Dynamics speaks to Freddy White at SLAS 2014.
14 February 2014 | By EBiSC
A consortium of 26 partners has been formed to establish the “European Bank for induced pluripotent Stem Cells” (EBiSC) with support from the IMI.
Despite the ever increasing efforts being expended for drug discovery purposes, the number of approved drugs remains relatively static. A variety of explanations have been provided to explain this observation and initiatives to remedy this situation have been implemented. Many of these initiatives are still works-in-progress and whether these will…
29 October 2013 | By Kenji Schorpp, Assay Development and Screening Scientist, Helmholtz Center.
Kenji Schorpp, Assay Development and Screening Scientist, talks to Drug Target Review about his work at the Helmholtz Center...
